ArticleFoods (Basel, Switzerland)2025
Investigating the Alleviating Effect of Fucoidan from
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mung Bean Peptides Alleviate Dextran-Sulfate-Sodium-Induced Colitis Symptoms in Mice by Protecting the Intestinal Mechanical Barrier and Regulating Gut Microbiota.Foods (Basel, Switzerland) · 2025Article
- Research progress on natural products in regulating the gut microbiota in Parkinson's disease.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFucoidan from
methodsIn this study, Aj-FUC was extracted, and its basic structure was characterized, while the alleviating efficacy of Aj-FUC on ulcerative colitis (UC) was investigated using C57BL/6 mice. The improvement of Aj-FUC on the fecal gut microbiota in healthy individuals and inflammatory bowel disease (IBD) patients was explored using in vitro simulated fecal fermentation.
resultsThe results reflected that Aj-FUC treatment attenuated the histopathological damage associated with colitis, reduced the levels of IL-6, IL-1β, and TNF-α. Aj-FUC treatment also upregulated the expression of ZO-1 and occludin, thereby aiding in the repair of the intestinal barrier. Furthermore, Aj-FUC enhanced the levels of short-chain fatty acids (SCFAs) and helped restore the balance of gut microbiota, particularly by increasing the relative abundance of
conclusionsIn conclusion, this study highlights that Aj-FUC can alleviate UC by modulating the levels of inflammatory factors, improving the intestinal barrier, and regulating the intestinal flora in a variety of ways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.